Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric or Substance Use Disorders
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.586 alerts
Get alerted when Policy 5.01.586 changes without checking for updates manually.
Monitor payer policy activity
Defines coverage stance for intravenous infusion of anesthetic agents (including ketamine and lidocaine) for chronic pain syndromes and psychiatric/substance use disorders, and describes associated coding and evidence considerations for providers.
IV ketamine is considered investigational in any setting or in conjunction with any other service, not just when it is either monotherapy or in conjunction with psychotherapy.
In addition to IV ketamine, any office visits, clinic visits, psychotherapy sessions, evaluation and management sessions, or any other sessions during which IV ketamine is administered are also considered investigational.
HCPCS code J2001 was removed from the policy (termed October 1, 2024).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.